Moreover, it was demonstrated that PI3K activity is a main predictor of MEK-inhibitor resistance in KRAS-driven colorectal cancer [17, 18] and that the addition of a selective PI3K inhibitor could reverse acquired resistance to MEK-inhibition [19]. This evidence concerns the gene MAP2K7 and colorectal cancer.